ETS2 and thyroid gland carcinoma: ETS2 was remarkably increased in colon adenocarcinoma (COAD), PAAD, rectum adenocarcinoma (READ), and STAD, while decreased in breast invasive carcinoma (BRCA), bladder urothelial carcinoma (BLCA), DLBC, GBM, kidney chromophobe (KICH), LUAD, LUSC, prostate adenocarcinoma (PRAD), SKCM, thyroid carcinoma (THCA), UCEC, and UCS.